Teva Pharma Q3 Beats Market, Lifts FY24 Outlook
Teva Pharma Q3 Beats Market, Lifts FY24 Outlook; Stock Up
(RTTNews) - Teva Pharmaceutical Industries Ltd. (TEVA) Wednesday reported a loss in its third quarter, compared to prior year's profit, despite higher revenues. However, adjusted earnings and top line beat market estimates, and the firm lifted its fiscal 2024 forecast.
Teva stock plunged Wednesday — sacrificing an earlier breakout — despite beating third-quarter expectations and raising its guidance.
EPS, expectations were $0.66. Operator: Hello, and welcome to the Q3 2024 Teva Pharmaceuticals Industries Limited Earnings ...
As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...
Teva Pharmaceutical Industries Ltd (TEVA) reports a 15% revenue increase and raises 2024 guidance, despite facing legal and ...
Teva Pharmaceutical Industries expects to work productively with the incoming Trump administration in the United States, ...
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the ...
QRG Capital Management Inc. cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 1.6% during the third quarter, according to the company in its most recent Form ...
On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its ...
Phase 3 trial results show Teva's TEV-'749 improves social functioning in adults with schizophrenia without post-injection ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback